Compile Data Set for Download or QSAR
Report error Found 450 Enz. Inhib. hit(s) with all data for entry = 10503
TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541850(US11267824, Example 48a)
Affinity DataIC50: 4.37nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541856(US11267824, Example 68a)
Affinity DataIC50: 4.63nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541966(US11267824, Example 172)
Affinity DataIC50: 4.97nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541818(US11267824, Example 36a)
Affinity DataIC50: 5.03nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541886(US11267824, Example 96a | US11267824, Example 96)
Affinity DataIC50: 5.32nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541817(US11267824, Example 36)
Affinity DataIC50: 5.38nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541849(US11267824, Example 47b)
Affinity DataIC50: 5.99nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541862(US11267824, Example 73a)
Affinity DataIC50: 6.45nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541891(US11267824, Example 100)
Affinity DataIC50: 6.63nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541974(US11267824, Example 180)
Affinity DataIC50: 6.65nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541969(US11267824, Example 175)
Affinity DataIC50: 7.04nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541926(US11267824, Example 133)
Affinity DataIC50: 7.07nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541771(US11267824, Example 1a)
Affinity DataIC50: 7.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541892(US11267824, Example 100a)
Affinity DataIC50: 7.82nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541830(US11267824, Example 48)
Affinity DataIC50: 8.40nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541903(US11267824, Example 110)
Affinity DataIC50: 9.81nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541773(US11267824, Example 2a)
Affinity DataIC50: 10.3nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541886(US11267824, Example 96a | US11267824, Example 96)
Affinity DataIC50: 10.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541888(US11267824, Example 97)
Affinity DataIC50: 10.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541898(US11267824, Example 105)
Affinity DataIC50: 10.6nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541924(US11267824, Example 131)
Affinity DataIC50: 11.3nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541828(US11267824, Example 46)
Affinity DataIC50: 11.4nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541856(US11267824, Example 68a)
Affinity DataIC50: 11.6nMAssay Description:TDO2: Recombinant human TDO comprising amino acids 19-407 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is inc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541774(US11267824, Example 3a)
Affinity DataIC50: 11.7nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541810(US11267824, Example 30)
Affinity DataIC50: 12.1nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541902(US11267824, Example 109)
Affinity DataIC50: 13.6nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541959(US11267824, Example 165)
Affinity DataIC50: 14.2nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541855(US11267824, Example 68)
Affinity DataIC50: 14.4nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541848(US11267824, Example 47a)
Affinity DataIC50: 15nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541770(US11267824, Example 1)
Affinity DataIC50: 15.1nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541775(US11267824, Example 4a)
Affinity DataIC50: 15.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541826(US11267824, Example 44)
Affinity DataIC50: 15.8nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541934(US11267824, Example 140a)
Affinity DataIC50: 15.8nMAssay Description:TDO2: Recombinant human TDO comprising amino acids 19-407 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is inc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541798(US11267824, Example 20)
Affinity DataIC50: 16.1nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541930(US11267824, Example 137)
Affinity DataIC50: 16.3nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541776(US11267824, Example 5a)
Affinity DataIC50: 16.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541806(US11267824, Example 27)
Affinity DataIC50: 17.2nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541946(US11267824, Example 152)
Affinity DataIC50: 18.4nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541981(US11267824, Example 187)
Affinity DataIC50: 18.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541932(US11267824, Example 139)
Affinity DataIC50: 18.7nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541829(US11267824, Example 47)
Affinity DataIC50: 18.8nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541815(US11267824, Example 34a)
Affinity DataIC50: 19.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541933(US11267824, Example 140)
Affinity DataIC50: 19.9nMAssay Description:TDO2: Recombinant human TDO comprising amino acids 19-407 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is inc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541851(US11267824, Example 50a)
Affinity DataIC50: 20nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541886(US11267824, Example 96a | US11267824, Example 96)
Affinity DataIC50: 20nMAssay Description:TDO2: Recombinant human TDO comprising amino acids 19-407 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is inc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541803(US11267824, Example 24a)
Affinity DataIC50: 20.5nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541852(US11267824, Example 63a)
Affinity DataIC50: 20.9nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541809(US11267824, Example 29)
Affinity DataIC50: 21.4nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541980(US11267824, Example 186)
Affinity DataIC50: 21.8nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM541808(US11267824, Example 28a)
Affinity DataIC50: 22.2nMAssay Description:IDO1: Recombinant full-length human IDO1 with a N-terminal hexahistidine tag expressed in E. coli and purified to homogeneity is incubated at a final...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2022
Entry Details
US Patent

Displayed 1 to 50 (of 450 total ) | Next | Last >>
Jump to: